FDA Green Lights Novo Nordisk Diabetes Drug   Ozempic is a once-weekly diabetes treatment


Original post, click here
Share this...
Tweet about this on TwitterShare on FacebookShare on LinkedInEmail this to someoneShare on Google+Share on RedditPin on Pinterest

The U.S. Food and Drug Administration has given Novo Nordisk’s latest diabetes drug, Ozempic, a green light.

The agency announced the decision Tuesday, Reuter’s reports.

Novo Nordisk developed the weekly injection in an effort to pull some market share from Trulicity, another once-weekly injection for type 2 diabetes.

According to the Reuters report, the company looks to set the price for the treatment at $676 per prescription.

Click here to read the full report on Reuters.